Plozasiran sodium
Based on 1 Customer Validation
Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
For research use only. We do not sell to patients.
- Purity: 97.94%
- CAS No.: 2379776-41-5
- Molecular Weight:15618.77 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
|
apoC3 |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2379776-41-5
-
Appearance Solid
-
Molecular Weight 15618.77 (free acid)
-
Color White to off-white
-
SMILES
[Plozasiran (sodium)]
-
Synonyms
ARO-APOC3 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620-630. [Content Brief]
[2]. Gaudet D, Clifton P, Sullivan D, et al. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. NEJM Evid. 2023;2(12):EVIDoa2200325. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)